Altasciences Partners with VoxCell BioInnovation to Integrate 3D Bioprinting Technology into Preclinical Drug Development
核心洞察
Altasciences (搜索) and VoxCell BioInnovation (搜索) have formed a strategic collaboration to enhance preclinical research by integrating 3D bioprinted tissue platforms into early-phase drug development services.
The partnership combines Altasciences (搜索)' comprehensive drug development capabilities with VoxCell's cutting-edge 3D tissue technology to create more predictive and human-relevant preclinical testing environments.
VoxCell's proprietary bioprinted tissues closely mimic human tumors (搜索) and biological structures, offering advanced platforms for evaluating drug efficacy, safety, and toxicity before animal or human studies.
Altasciences (搜索), a fully integrated drug development solution company, and VoxCell BioInnovation (搜索), a leader in 3D bioprinting and human-like tissue modeling, have announced a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. The partnership represents a significant advancement in bringing next-generation tissue modeling technology to early-stage drug development.
Strategic Integration of 3D Bioprinting Technology
The collaboration combines Altasciences (搜索)' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell's high-resolution 3D bioprinted tissue platforms into Altasciences' discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies.
"We're proud to partner with VoxCell BioInnovation (搜索) to bring next-generation tissue modeling into the early stages of drug development," said Steve Mason, Co-Chief Operating Officer at Altasciences (搜索). "This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients."
Advanced Tissue Modeling Platform
VoxCell's proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors (搜索) and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity before moving into animal or human studies. The company develops 3D bioprinted vascularized human-like tissue models that closely replicate native biology, using a proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™.
These complex tissue models mirror patient biopsy samples in structure and function, delivered as ready-to-use, perfusable models. The technology serves pharmaceutical companies, biotech firms, contract research organizations, and academic researchers seeking to reduce translational gaps and accelerate biomedical innovation.
Initial Focus and Future Expansion
The collaboration will focus initially on drug screening for ocular indications (搜索), with plans to expand into additional therapeutic areas and applications. "Our mission has always been to make drug screening more human-relevant and predictive," said Karolina Valente, CEO of VoxCell BioInnovation (搜索). "Altasciences (搜索) shares this forward-thinking approach, and we're excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions."
Company Backgrounds
Altasciences (搜索) has been operating for over 30 years, offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. The company's integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, research support, medical writing, biostatistics, clinical monitoring, and data management.
VoxCell BioInnovation (搜索) is a biotechnology startup founded in 2020 in Victoria, British Columbia, Canada. The company is dedicated to advancing the future of in vitro modeling by creating novel testing platforms for oncology (搜索) research and drug development. Their consumable products are designed to provide pharmaceutical companies with more predictive, physiologically relevant research tools.
The partnership represents a shared vision to transform early-stage research through innovation, integration, and smarter science, ultimately delivering better outcomes for patients worldwide.